Nicholas A. Blondin, MD, is a Yale Medicine neurologist who specializes in treating benign (noncancerous) and malignant (cancerous) brain tumors, brain and spine metastasis, and neurological symptoms of cancer such as seizures, cognitive impairment, headaches, gait disturbance, and weakness. He cares for patients at Smilow Cancer Hospital in New Haven and the Smilow Cancer Hospital Cancer Care Center in Trumbull.
“I love developing a strong doctor-patient relationship with my patients,” Dr. Blondin says. “I believe that a strong, trusting relationship is critical for me to help patients achieve their treatment goals and have the best possible quality of life.”
Dr. Blondin believes in “shared decision making,” a process he uses to create a treatment plan that will be best for each patient. “With a difficult diagnosis, I am open and honest but also work to provide hope that treatment will be effective,” Dr. Blondin says. “I let patients know that I will always be there for them, and I will support them in all phases of treatment.”
Together with a team of doctors at Smilow, he is able to help more patients achieve better outcomes. “In neuro-oncology, I rely on additional specialists such as neurosurgeons, radiation oncologists, pathologist, and neuro-radiologists in order to provide the best care for my patients,” he says.
Dr. Blondin is an active investigator for clinical trials for brain tumor patients through Yale Cancer Center and is an assistant professor of clinical neurology at Yale School of Medicine.
A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma - CheckMate 548: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 548